$LXRX - Inpefa FDA Approved - Inverse H&S - BOOM BOOM ROOM

NASDAQ:LXRX   Lexicon Pharmaceuticals, Inc.
This could be a game changer. Marketcap of Lexicon Pharm that produces Inpefa is only $538M with plenty of cash on hand. Competitor drugs Jardiance from LLY and Farxiga from AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out commercialization and sales at the end of June. This should be a fun ride! This is my own opinion and should not be taken as financial advice. Own your own trades.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.